Clinical trial · Interventional
Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis
NCT02590510CI-TRIAL-00024505unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to compare the effect of 10 mg and 15 mg methotrexate in the treatment of meningeal carcinomatosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Meningeal Carcinomatosis | Meningeal Carcinomatosis | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| methotrexate | Drug | Methotrexate | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- The small dose of group
- description
- The dose of methotrexate is 10 mg
- interventionNames
- Drug: methotrexate
- type
- ACTIVE_COMPARATOR
- label
- The high dose of group
- description
- The dose of methotrexate is 15 mg
- interventionNames
- Drug: methotrexate
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- one year
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
Show eligibility criteria text
Inclusion Criteria: * age 14 or more * a history of solid tumor * a new clinical neurological signs and symptoms * a typical CT(Computerized Tomography,CT) or MRI(Magnetic Resonance Imaging,MRI) imaging findings * tumor cells in cerebrospinal fluid Exclusion Criteria: * KPS score \<60 * the tumor patients with organ failure * bacteria, fungi or viral meningitis
References
Publications (0)
Data not yet available
No reference posted for this study.